175 related articles for article (PubMed ID: 18381380)
1. HER2 testing in the UK: further update to recommendations.
Walker RA; Bartlett JM; Dowsett M; Ellis IO; Hanby AM; Jasani B; Miller K; Pinder SE
J Clin Pathol; 2008 Jul; 61(7):818-24. PubMed ID: 18381380
[TBL] [Abstract][Full Text] [Related]
2. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.
Bartlett JM; Starczynski J; Atkey N; Kay E; O'Grady A; Gandy M; Ibrahim M; Jasani B; Ellis IO; Pinder SE; Walker RA
J Clin Pathol; 2011 Aug; 64(8):649-53. PubMed ID: 21690244
[TBL] [Abstract][Full Text] [Related]
3. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
4. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
5. HER2 testing of multifocal invasive breast carcinoma: how many blocks are enough?
Bethune GC; Mullen JB; Chang MC
Am J Clin Pathol; 2013 Oct; 140(4):588-92. PubMed ID: 24045558
[TBL] [Abstract][Full Text] [Related]
6. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
7. External quality assurance of HER2 fluorescence in situ hybridisation testing: results of a UK NEQAS pilot scheme.
Bartlett JM; Ibrahim M; Jasani B; Morgan JM; Ellis I; Kay E; Magee H; Barnett S; Miller K
J Clin Pathol; 2007 Jul; 60(7):816-9. PubMed ID: 16963466
[TBL] [Abstract][Full Text] [Related]
8. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance.
Lambein K; Van Bockstal M; Vandemaele L; Geenen S; Rottiers I; Nuyts A; Matthys B; Praet M; Denys H; Libbrecht L
Am J Clin Pathol; 2013 Oct; 140(4):561-6. PubMed ID: 24045554
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer HER2 equivocal cases: is there an alternative to FISH testing? A pilot study using two different antibodies sequentially.
Yosepovich A; Avivi C; Bar J; Polak-Charcon S; Mardoukh C; Barshack I
Isr Med Assoc J; 2010 Jun; 12(6):353-6. PubMed ID: 20928989
[TBL] [Abstract][Full Text] [Related]
10. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
[TBL] [Abstract][Full Text] [Related]
11. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
12. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
13. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
[TBL] [Abstract][Full Text] [Related]
14. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
15. A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer.
Di Palma S; Collins N; Bilous M; Sapino A; Mottolese M; Kapranos N; Schmitt F; Isola J
J Clin Pathol; 2008 Jun; 61(6):757-60. PubMed ID: 18326010
[TBL] [Abstract][Full Text] [Related]
16. External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.
Bartlett JM; Ibrahim M; Jasani B; Morgan JM; Ellis I; Kay E; Connolly Y; Campbell F; O'Grady A; Barnett S; Miller K
Am J Clin Pathol; 2009 Jan; 131(1):106-11. PubMed ID: 19095573
[TBL] [Abstract][Full Text] [Related]
17. HER2/neu revisited: quality and interpretive issues.
Ahmed SS; Iqbal J; Thike AA; Lim AS; Lim TH; Tien SL; Tan PH
J Clin Pathol; 2011 Feb; 64(2):120-4. PubMed ID: 21131629
[TBL] [Abstract][Full Text] [Related]
18. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
19. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
20. Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
J Clin Pathol; 2011 Jun; 64(6):490-2. PubMed ID: 21415056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
